We are live on ! Find out more
SCM

Superstring Capital Management Portfolio holdings

AUM $140M
1-Year Est. Return 323.19%
This Fund
S&P 500
This Quarter Est. Return
+21.19%
1 Year Est. Return
+323.19%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$151M
AUM Growth
+$11.1M
Cap. Flow
+$7.92M
Cap. Flow %
5.24%
Top 10 Hldgs %
64.45%
Holding
47
New
17
Increased
12
Reduced
7
Closed
10

Top Buys

Rank Stock Value
1
NKTX icon
Nkarta
NKTX
+$8.75M
2
CYTK icon
Cytokinetics
CYTK
+$7.84M
3
CABA icon
Cabaletta Bio
CABA
+$6.24M
4
SVRA icon
Savara
SVRA
+$6.04M
5
BBIO icon
BridgeBio Pharma
BBIO
+$5.01M

Top Sells

Rank Stock Value
1
IMGN
Immunogen Inc
IMGN
+$17.7M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$8.69M
3
IMVT icon
Immunovant
IMVT
+$8.58M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$3.87M
5
LNTH icon
Lantheus
LNTH
+$3.4M

Sector Composition

Rank Sector Weight
1 Healthcare 96.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALLK
26
DELISTED
Allakos
ALLK
$1.55M 1.03%
+1,233,739
New +$1.92M
CTMX icon
27
CytomX Therapeutics
CTMX
$798M
$1.48M 0.98%
+679,403
New +$1.25M
ANNX icon
28
Annexon
ANNX
$965M
$1.12M 0.74%
+155,728
New +$809K
RNAM
29
DELISTED
Avidity Biosciences
RNAM
$945K 0.62%
+37,031
New +$580K
LYRA
30
DELISTED
LYRA THERAPEUTICS INC
LYRA
$904K 0.6%
+2,906
New +$774K
INZY
31
DELISTED
Inozyme Pharma
INZY
$864K 0.57%
112,739
-11,205
-9% -$61.5K
AUPH icon
32
Aurinia Pharmaceuticals
AUPH
$2.05B
$494K 0.33%
+98,691
New +$669K
KALV
33
DELISTED
KalVista Pharmaceuticals
KALV
$380K 0.25%
+32,025
New +$427K
ALPN
34
DELISTED
Alpine Immune Sciences Inc
ALPN
$358K 0.24%
+9,038
New +$267K
SPRB
35
Spruce Biosciences
SPRB
$122M
$346K 0.23%
5,870
+4,286
+271% +$1.09M
LSB
36
DELISTED
LakeShore Biopharma
LSB
$216K 0.14%
30,792
– –
SY
37
So-Young International
SY
$170M
$199K 0.13%
182,742
-613,317
-77% -$648K
IMTX icon
38
Immatics
IMTX
$1.28B
– –
-79,213
Closed -$834K
IMVT icon
39
Immunovant
IMVT
$8B
– –
-203,592
Closed -$8.58M
KRYS icon
40
Krystal Biotech
KRYS
$10.1B
– –
-16,086
Closed -$2M
LNTH icon
41
Lantheus
LNTH
$6.84B
– –
-54,896
Closed -$3.4M
NBIX icon
42
Neurocrine Biosciences
NBIX
$17.2B
– –
-29,346
Closed -$3.87M
PTGX icon
43
Protagonist Therapeutics
PTGX
$8.49B
– –
-379,143
Closed -$8.69M
QTRX icon
44
Quanterix
QTRX
$187M
– –
-71,760
Closed -$1.96M
SLRN
45
DELISTED
ACELYRIN
SLRN
– –
-356,924
Closed -$2.66M
FUSN
46
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
– –
-45,801
Closed -$440K
IMGN
47
DELISTED
Immunogen Inc
IMGN
– –
-598,072
Closed -$17.7M
1
2

Similar funds

GIM
Guild Investment Management Los Angeles, California $140M AUM 28.67% 1-Year Est. Return
SLWM
Stone Loft Wealth Management West Chester, Pennsylvania $140M AUM
NWA
Northwest Wealth Advisors Bellingham, Washington $140M AUM
WCM
WealthTrak Capital Management Virginia Beach, Virginia $140M AUM 17% 1-Year Est. Return
JD6
J Digital 6 Chicago, Illinois $140M AUM
CPC
CFC Planning Company Cicero, Indiana $140M AUM 22.33% 1-Year Est. Return
CFG
Chapman Financial Group Kailua, Hawaii $140M AUM 15.83% 1-Year Est. Return
RC
Rexford Capital Bellaire, Texas $140M AUM 28.19% 1-Year Est. Return

Superstring Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, Superstring Capital Management held 47 positions worth $151M, up 7.9% from $140M the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Superstring Capital Management deployed $7.92M of net new capital in Q1 2024, opening 17 new positions and adding to 12 existing holdings. Its largest new stake was Cabaletta Bio: 290,797 shares worth $4.96M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier.

On the sell side, the largest reduction was Ionis Pharmaceuticals, an estimated $3.28M trimmed.

  • Superstring Capital Management's largest Q1 2024 buy was Cabaletta Bio: 290,797 shares worth $4.96M.
  • Superstring Capital Management added most to Nkarta in Q1 2024, an estimated $8.75M increase.
  • Superstring Capital Management's biggest Q1 2024 reduction was Ionis Pharmaceuticals, cutting an estimated $3.28M.
  • Superstring Capital Management fully exited Immunogen Inc in Q1 2024, selling an estimated $17.7M.
  • Superstring Capital Management's ten largest holdings make up 64% of its $151M portfolio in Q1 2024.
  • Superstring Capital Management opened 17 new positions and closed 10 in Q1 2024.
  • Superstring Capital Management's portfolio value rose 7.9% quarter-over-quarter to $151M.

Based on Superstring Capital Management's 13F filing for Q1 2024, filed 15 May 2024.